Drugs / Calcitriol
Calcitriol
also known as
1,25 Dihydroxy-Vitamin D3 · DN101 · Rocaltrol · 1,25-(OH)₂D₃ · 1,25-dihydroxyvitamin D · Vitamin D · 1, 25 dihydroxycholecalciferol · Calcijex · +7 more
Small molecule targets REN via inhibition
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | VECTICAL | — | 2020-07-17 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | CALCIJEX | — | 1996-10-22 – 2001-11-16 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | ROCALTROL | — | 1982-04-22 – 1998-11-20 | fda.gov ↗ |
| Approved | US (FDA) | ROCALTROL | — | 1978-08-17 | fda.gov ↗ |
Trials 84 · started per year
today
US approved 1978
1
1
1
1
1
1
2
2
2
1
6
5
6
5
4
4
5
8
5
2
4
3
2
2
5
1
1
2
197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials · 1 missed | ||||||
| Phase 0 | NCT03563235 | Sep 2019 → Sep 2021 | postmenopausal osteoporosis | Fujian Academy of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 0 | NCT03748966 | Mar 2019 → Mar 2025 | X-linked dominant hypophosphatemic rickets | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 0 | NCT04643821 | Jan 2015 → Apr 2017 | brain hypoxia - ischemia | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 0 | NCT01988116 | Oct 2013 → Jun 2015 | anemia due to chronic disorder, chronic kidney disease | University of Alabama at Birmingham | Completed | Missed primary |
| Phase 0 | NCT00585442 | May 2007 → Jun 2008 | hypertensive disorder, vitamin D deficiency | University of Utah | Terminated | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT06209229 | May 2022 → May 2023 | non-small cell lung carcinoma | MIPO Clinic | Completed | No outcome recorded |
| Phase 1 | NCT04386811 | Aug → Sep 2020 | attention deficit-hyperactivity disorder | Yale University | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01588522 | Sep 2012 → Feb 2017 | chemotherapy-induced alopecia | BPGbio | Completed | No outcome recorded |
| Phase 1 | NCT01526278 | Oct 2011 → Jul 2012 | osteoporosis | Yuyu Pharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01235728 | Nov 2010 → Apr 2011 | psoriasis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00055263 | Mar 2002 → ? | neoplasm | Novacea | Completed | No outcome recorded |
| Phase 1 | NCT00004928 | Oct 1999 → Oct 2004 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/26 trials · 1 missed | ||||||
| Phase 1/2 | NCT05920512 | Apr 2022 → Apr 2025 | hemophilia | Xue-chun Lu | Unknown | No outcome recorded |
| Phase 1/2 | NCT00953849 | Nov 2009 → Dec 2015 | oral cavity cancer | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 1/2 | NCT00794547 | Dec 2008 → Oct 2011 | non-small cell lung carcinoma | University of Michigan Rogel Cancer Center | Terminated | Missed primary |
| Phase 1/2 | NCT00536991 | Oct 2006 → Oct 2016 | prostate adenocarcinoma | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00287170 | Jul 2006 → Dec 2007 | Crohn disease | Teva GTC | Completed | No outcome recorded |
| Phase 1/2 | NCT00066885 | Jun 2003 → Dec 2005 | non-small cell lung carcinoma | Novacea | Completed | No outcome recorded |
| Phase 220 trials · 3 missed | ||||||
| Phase 2 | NCT07842120 | Apr → Dec 2026 expected | — | Ghufran Dhari Awad | Recruiting | No outcome recorded |
| Phase 2 | NCT06288451 | Mar 2024 → Feb 2027 expected | chronic renal failure syndrome, renal osteodystrophy | University of Washington | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05765617 | Jul → Sep 2021 | COVID-19 | Universitas Sebelas Maret | Completed | No outcome recorded |
| Phase 2 | NCT02962102 | Apr 2017 → Jul 2020 | acute kidney injury | David Leaf | Completed | Missed primary |
| Phase 2 | NCT03261336 | Jan 2017 → Feb 2018 | castration-resistant prostate carcinoma | Donald Trump, MD | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02224144 | Aug 2014 → Oct 2016 | bone resorption disease, calcinosis, end stage renal failure | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT02061384 | Aug 2014 → Dec 2018 | Klinefelter syndrome, partial chromosome Y deletion | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT01863641 | Apr → Oct 2013 | systemic lupus erythematosus | Guilan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01689441 | Feb 2013 → Feb 2014 | infectious disease with sepsis | Brigham and Women's Hospital | Completed | Missed primary |
| Phase 2 | NCT01293682 | Nov 2010 → Aug 2018 | breast cancer | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT01039181 | Jan 2010 → Oct 2011 | intrahepatic cholangiocarcinoma | National Science and Technology Development Agency, Thailand | Unknown | No outcome recorded |
| Phase 2 | NCT00904033 | Dec 2008 → Jan 2018 | bone disorder, breast cancer | University of Rochester | Completed | Mixed |
| Phase 2 | NCT00419666 | Aug 2006 → Sep 2009 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 2 | NCT00285675 | Apr 2006 → Jan 2008 | hormone-resistant prostate carcinoma, non-small cell lung carcinoma | Novacea | Unknown | No outcome recorded |
| Phase 2 | NCT00383487 | Mar 2005 → Jul 2007 | prostate cancer | Stanford University | Terminated | No outcome recorded |
| Phase 2 | NCT00182741 | Sep 2004 → Aug 2006 | prostate cancer | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00030069 | Sep 2001 → Sep 2007 | myelodysplastic syndrome | University of Pittsburgh | Completed | No outcome recorded |
| Phase 2 | NCT00004340 | Jun 1995 → ? | end stage renal failure, renal osteodystrophy | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 2 | NCT00001304 | Oct 1991 → Mar 2014 | hypoparathyroidism | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 2 | NCT01120119 | — | type 1 diabetes mellitus | Campus-Bio-Medico University | Completed | Missed primary |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02410005 | Oct 2014 → Sep 2015 | diabetic kidney disease | Weill Cornell Medical College in Qatar | Terminated | No outcome recorded |
| Phase 2/3 | NCT00043576 | Aug 2002 → Dec 2005 | prostate cancer | Novacea | Unknown | No outcome recorded |
| Phase 37 trials · 2 missed | ||||||
| Phase 3 | NCT03216564 | May 2017 → May 2019 | diabetic kidney disease | Hamad Medical Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT03140449 | Sep 2013 → Nov 2016 | benign vascular tumor | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02282813 | Apr 2013 → May 2015 | chronic kidney disease, secondary hyperparathyroidism of renal origin, vitamin D deficiency | OPKO Health, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01384539 | Jul 2011 → Sep 2015 | arterial disorder, chronic kidney disease | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 3 | NCT01313221 | Apr 2011 → Dec 2012 | psoriasis | Amgen | Completed | Missed primary |
| Phase 3 | NCT00486512 | Jun 2007 → Nov 2010 | adenomatous colon polyp | Colotech A/S | Terminated | Missed primary |
| Phase 3 | NCT00273338 | Jan 2006 → Nov 2007 | prostate cancer | Novacea | Terminated | No outcome recorded |
| Phase 421 trials | ||||||
| Phase 4 | NCT07670611 | Apr → Jul 2026 overdue | cholestasis, liver disorder, vitamin D deficiency | Chulalongkorn University | Recruiting | No outcome recorded |
| Phase 4 | NCT04801303 | Aug 2021 → Sep 2022 | Friedreich ataxia | Berta Alemany | Completed | No outcome recorded |
| Phase 4 | NCT03820518 | Jan 2017 → Dec 2021 | X-linked hypophosphatemic rickets | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01561222 | Jul 2015 → Mar 2016 | chronic kidney disease | Taixing People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02186665 | Jul 2014 → Nov 2015 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT02125279 | May 2014 → May 2018 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT01820832 | Mar 2013 → Dec 2014 | chronic kidney disease, proteinuria | Huashan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01766440 | Mar 2013 → Nov 2015 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT01765010 | Jan → Mar 2013 | osteoporosis | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01725113 | Nov 2012 → Dec 2013 | hypercalcemia disease, hyperphosphatemia, kidney failure, secondary hyperparathyroidism | Winthrop University Hospital | Terminated | No outcome recorded Stop: Business |
| Phase 4 | NCT01673204 | Oct 2012 → Apr 2014 | diabetic kidney disease | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01512862 | Jan → Dec 2012 | proteinuria | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01012713 | Jun 2010 → Dec 2014 | psoriasis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT00988637 | Oct 2009 → Mar 2010 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00862693 | Mar 2009 → Aug 2010 | autoimmune disease, glomerulonephritis | Peking University First Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00664430 | Jan → Jun 2009 | secondary hyperparathyroidism | Abbott | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01115543 | Aug 2008 → Aug 2009 | end stage renal failure, secondary hyperparathyroidism of renal origin | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT00508898 | May 2008 → Sep 2009 | lupus nephritis, proteinuria, systemic lupus erythematosus | Chinese University of Hong Kong | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT00319761 | May 2006 → Sep 2007 | IgA glomerulonephritis | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT00073710 | Sep 2004 → ? | chronic kidney disease, secondary hyperparathyroidism | Abbott | Completed | No outcome recorded |
| Phase 4 | NCT00062699 | Apr 2003 → ? | end stage renal failure | Abbott | Terminated | No outcome recorded |
| Phase not applicable16 trials · 1 missed | ||||||
| — | NCT07200349 | Nov 2025 → Sep 2026 overdue | — | Al-Azhar University | Not yet recruiting | No outcome recorded |
| — | NCT06464718 | Jun → Dec 2022 | — | Frontier Medical and Dental College, Abbotabad | Completed | No outcome recorded |
| — | NCT05415254 | Jun → Aug 2022 | COVID-19, vitamin D deficiency | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT05298163 | Apr → Oct 2022 | diabetic kidney disease | Indonesia University | Unknown | Mixed |
| — | NCT04967469 | Sep 2020 → Dec 2023 | end stage renal failure | Department of Medical Services Ministry of Public Health of Thailand | Completed | No outcome recorded |
| — | NCT05202496 | Nov 2019 → Apr 2021 | — | Postgraduate Institute of Dental Sciences Rohtak | Completed | No outcome recorded |
| — | NCT01635062 | Sep 2012 → Dec 2015 | obesity disorder, type 2 diabetes mellitus | Brigham and Women's Hospital | Completed | Missed primary |
| — | NCT01237028 | Mar 2011 → Aug 2016 | IgA glomerulonephritis | Yonsei University | Completed | No outcome recorded |
| — | NCT01026363 | Dec 2009 → Jul 2014 | chronic kidney disease, vitamin D deficiency | Massachusetts General Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00690924 | Jul 2008 → Mar 2017 | lung cancer, nicotine dependence, precancerous condition | Roswell Park Cancer Institute | Completed | No outcome recorded |
| — | NCT00990678 | Apr 2008 → Feb 2010 | HIV infectious disease | Hvidovre University Hospital | Completed | No outcome recorded |
| — | NCT00926315 | Jul 2007 → Jun 2013 | breast cancer | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| — | NCT00482157 | Feb → Nov 2007 | prostate cancer | Stanford University | Withdrawn | No outcome recorded |
| — | NCT00427804 | Jan 2007 → Aug 2009 | Crohn disease, rheumatoid arthritis | Atlanta VA Medical Center | Completed | No outcome recorded |
| — | NCT00006275 | Jul 2000 | psoriasis | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| — | NCT00004468 | Oct 1998 → ? | psoriasis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy34 trials | ||||||
| Phase 0 | NCT04826133 Comparator | Mar 2019 → Jan 2020 | substance-related disorder | Yale University | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04286529 Comparator | Oct 2020 → May 2021 | prediabetes syndrome | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT00925704 Comparator | Jun → Jul 2009 | — | Shire | Completed | No outcome recorded |
| Phase 1 | NCT00298545 Comparator | Nov 2005 → May 2009 | adenocarcinoma, colorectal adenoma, polyp | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT01969656 Comparator | ? → Jun 2004 | postmenopausal osteoporosis | Deltanoid Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01358045 Comparator | Nov 2011 → Feb 2013 | basal cell carcinoma | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00623974 Background | May 2008 → Jun 2010 | — | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00536770 Comparator | Sep 2007 → ? | malignant pancreatic neoplasm | Novacea | Suspended | No outcome recorded |
| Phase 2 | NCT00960635 Comparator | Jun 2001 → Aug 2008 | type 1 diabetes mellitus | Institute of Diabetes Research, Helmholtz Zentrum München | Completed | No outcome recorded |
| Phase 3 | NCT06046820 Comparator | Nov 2023 → Jan 2026 | arterial calcification of infancy, autosomal recessive hypophosphatemic rickets | Inozyme Pharma | Terminated | No outcome recorded |
| Phase 3 | NCT02859896 Comparator | Jan 2017 → Jun 2025 | secondary hyperparathyroidism of renal origin | Sanofi | Terminated | Missed primary |
| Phase 3 | NCT01656512 Comparator | Oct 2011 → Jan 2014 | osteoporosis | Children's Cancer Hospital Egypt 57357 | Completed | No outcome recorded |
| Phase 3 | NCT00658788 Comparator | Mar 2008 → Jan 2009 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT00004402 Background | Nov 1999 → Jun 2000 | osteopetrosis | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| Phase 3 | NCT00000412 Comparator | Sep 1997 → Apr 2002 | osteoporosis | Columbia University | Completed | No outcome recorded |
| Phase 4 | NCT05902078 Comparator | Sep 2023 → Jun 2025 | disease of bone structure, postmenopausal osteoporosis | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04094805 Comparator | Oct 2020 → Mar 2021 | autoimmune thrombocytopenia | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT01748396 Background | Jul 2012 → Jan 2013 | chronic kidney disease | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01350934 Comparator | Jun 2011 → Jan 2013 | postmenopausal osteoporosis | Organon and Co | Completed | Met primary |
| Phase 4 | NCT01181531 Comparator | Oct 2010 → Jul 2012 | secondary hyperparathyroidism | Amgen | Completed | Missed primary |
| Phase 4 | NCT01768351 Comparator | Oct 2010 → Mar 2011 | anemia, chronic kidney disease | Federico II University | Completed | Met primary |
| Phase 4 | NCT01205880 Comparator | Dec 2009 → Jan 2010 | psoriasis | Emer, Jason, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01265615 Comparator | Oct 2009 → Apr 2010 | cardio-renal syndrome, chronic transplant rejection | Ural State Medical University | Completed | No outcome recorded |
| Phase 4 | NCT00823303 Comparator | Feb 2009 → May 2013 | chronic kidney disease, secondary hyperparathyroidism | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00752102 Comparator | Sep 2008 → Oct 2013 | calcinosis, chronic kidney disease, vitamin D deficiency | Joslin Diabetes Center | Completed | No outcome recorded |
| Phase 4 | NCT00712205 Comparator | Aug 2008 → Aug 2010 | asthma | Kantonsspital Baselland Bruderholz | Unknown | No outcome recorded |
| Phase 4 | NCT01388517 Comparator | Jan 2008 → Aug 2010 | pityriasis alba | Autonomous University of San Luis Potosí | Completed | No outcome recorded |
| Phase 4 | NCT00497900 Background | Aug 2007 → Sep 2011 | heart failure, vitamin D deficiency | Hvidovre University Hospital | Completed | No outcome recorded |
| — | NCT07640347 Comparator | Jul 2026 → May 2027 expected | secondary hyperparathyroidism of renal origin | Chittagong Medical College | Not yet recruiting | No outcome recorded |
| — | NCT05252884 Comparator | Jun 2022 → Oct 2024 | goiter, hyperthyroidism, thyroid cancer, thyroiditis | Centro de Excelencia en Enfermedades de Cabeza y Cuello | Completed | No outcome recorded |
| — | NCT04637360 Background | Jan → Dec 2018 | secondary hyperparathyroidism of renal origin | Min-Sheng General Hospital | Completed | No outcome recorded |
| — | NCT02273570 Background | Mar 2015 → Dec 2016 | secondary hyperparathyroidism of renal origin | Azienda Ospedaliera Sant'Anna | Unknown | No outcome recorded |
| — | NCT00800358 Comparator | Nov 2008 → Oct 2009 | chronic kidney disease, secondary hyperparathyroidism | Penang Hospital, Malaysia | Completed | Missed primary |
| — | NCT00459563 Comparator | Mar 2007 → Dec 2011 | hypertensive disorder | Atlanta VA Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2018-07-16 | Rockwell Medical Technologies, Inc. | Regulatory Calcitriol New Contract Manufacturing Submission Receives FDA Approval and Allows Rockwell Medical Commercialization of Calcitriol rockwellmed.com ↗
On July 11, 2018, Rockwell Medical received FDA approval of its Prior Approval Supplement for manufacturing Calcitriol. |
| 2018-05-08 | Rockwell Medical Technologies, Inc. | Regulatory Rockwell Medical Update on Calcitriol New Manufacturing Submission to FDA rockwellmed.com ↗ |
| 2018-03-20 | Takeda | Results New Data Presented at the Endocrine Society’s 2018 Annual Meeting Advances Understanding of the Rare Disease Chronic Hypoparathyroidism takeda.com ↗
Oral calcium and calcitriol doses were reduced by 53.4% and 75.7%, respectively, while albumin-adjusted serum calcium levels were maintained within the target range. |
| 2017-06-15 | Yuyu Pharma, Inc. | Results 유유제약, 골다공증 치료제 맥스마빌정 임상4상 골절예방효과 입증 yuyu.co.kr ↗
위 환자를 대상으로 맥스마빌정 투여 후 12개월 추적 관찰한 결과, 골다공증성 골절 발생율은 약 2.7%였고, 요추 골밀도 및 고관절 골밀도는 각각 5% 및 1.5% 개선되었다. |
| 2009-02-03 | Galderma R&D | Regulatory Galderma wins FDA Approval for Vectical ™ Ointment galderma.com ↗
Galderma Laboratories, L.P. today announced that the U.S. Food and Drug Administration (FDA) has approved Vectical ™ (calcitriol) Ointment 3mcg/g, a unique vitamin D3 product for the treatment of mild-to-moderate plaque psoriasis in adults. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-07-16 | Rockwell Medical Technologies, Inc. | Calcitriol New Contract Manufacturing Submission Receives FDA Approval and Allows Rockwell Medical Commercialization of Calcitriol rockwellmed.com ↗ |
| 2018-05-08 | Rockwell Medical Technologies, Inc. | Rockwell Medical Update on Calcitriol New Manufacturing Submission to FDA rockwellmed.com ↗ |
| 2018-03-20 | Takeda | New Data Presented at the Endocrine Society’s 2018 Annual Meeting Advances Understanding of the Rare Disease Chronic Hypoparathyroidism takeda.com ↗ |
| 2017-06-15 | Yuyu Pharma, Inc. | 유유제약, 골다공증 치료제 맥스마빌정 임상4상 골절예방효과 입증 yuyu.co.kr ↗ |
| 2016-06-21 | OPKO Health, Inc. | FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease opko.com ↗ |
| 2009-02-03 | Galderma R&D | Galderma wins FDA Approval for Vectical ™ Ointment galderma.com ↗ |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 122 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Calcitriol | “The participants were randomized to 1 of 3 daily treatments: (1) 0.5-1.0 µg calcitriol and 1200 IU (30 µg) cholecalciferol, (2) 1200 IU cholecalciferol, (3) placebo.” PMID 22592096 ↗ May 2012112“Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT)” NCT01181531 ↗ “Conventional therapy is defined as oral phosphate supplements and calcitriol or other active forms of vitamin D3 (or analogs).” NCT06046820 ↗ “Sodium valproate extended-release tablets 0.5g/day; sirolimus tablets 1mg/day and calcitriol capsules 0.25μg/day.” NCT05920512 ↗ “DN-101 is a pill containing calcitriol, a chemical related to vitamin D that is immediately active in your body.” NCT00055263 ↗ “Patients receive oral calcitriol weekly for 3 consecutive days and zoledronate IV monthly.” NCT00004928 ↗ “Calcitriol- 5000 units in the morning before meals every other day 21 days” NCT06209229 ↗ “Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit” NCT01656512 ↗ “any active vitamin D available in Italy (calcitriol and paricalcitol-” NCT02273570 ↗ “calcitriol ointment 3µg/g and clobetasol propionate spray 0.05%” NCT00988637 ↗ “Patients receive oral high dose pulse calcitriol on day 1” NCT00182741 ↗ |
| Known as | 1, 25 dihydroxycholecalciferol | “In vitro and in vivo calcitriol (1, 25 dihydroxycholecalciferol) is antiproliferative and potentiates the antitumor effects of cytotoxic agents” NCT00794547 ↗1“Calcitriol(1,25-dihydroxycholecalciferol, vitamin D3 analog)0.25 μg per day” NCT01237028 ↗ |
| Known as | 1,25 Dihydroxy-Vitamin D3 | “Calcitriol, an active form of vitamin D (1,25-dihydroxyvitamin-D3), is commonly used for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney...” NCT01512862 ↗4“A Phase I Study of 1,25 Dihydroxy-Vitamin D3 (Calcitriol) in Patients With Prostate Cancer” NCT00004928 ↗ “calcitriol (the active form of vitamin D, 1.25-dihydroxyvitamin D3 \[1,25-(OH)2D3\] )” NCT01120119 ↗ “1, 25 dihydroxy vitamin D3 (Calcitriol)” NCT00298545 ↗ “1,25-dihydroxy-vitamin D3 (calcitriol)” NCT00960635 ↗ |
| Known as | 1,25-(OH)₂D₃ | “Calcitriol (1,25-(OH)₂D₃) local injection • Agent: Calcitriol (1,25-(OH)₂D₃) Vitamin D3” NCT07842120 ↗2“calcitriol (the active form of vitamin D, 1.25-dihydroxyvitamin D3 \[1,25-(OH)2D3\] )” NCT01120119 ↗ “Calcitriol (1,25(OH)2D3) 0.25mcg capsule daily for eight weeks.” NCT04286529 ↗ |
| Known as | 1,25-D3 | “Preclinical studies demonstrated antiproliferative synergy of 1,25-D3 (calcitriol) with cisplatin.” PMID 23435876 ↗ Feb 2013 |
| Known as | 1,25-dihydroxyvitamin D | “The purpose of this study is to assess the efficacy of calcifediol (25-hydroxyvitamin D) and calcitriol (1,25-dihydroxyvitamin D) in preventing and reducing the severity of...” NCT02962102 ↗2“We investigated whether administration of 1,25-dihydroxyvitamin D (calcitriol) to critically ill patients with sepsis would have beneficial effects on markers of innate...” PMID 25029202 ↗ Sep 2014 “calcitriol (1,25-dihydroxyvitamin D, the active form of vitamin D)” NCT00427804 ↗ |
| Known as | 1,25D | “We conducted a phase 2, randomized, double-blind, multiple-dose, 3-arm clinical trial comparing oral calcifediol (25D), calcitriol (1,25D), and placebo among 150 critically ill...” PMID 40924491 ↗ Sep 2025 |
| Known as | 1a -25-dihydroxycholecalciferol | “Daily dose of 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol, Rocaltrol; Roche, Basel, Switzerland), 75 mg acetylsalicylic acid (ASA), and 1250 mg calcium carbonate (CaCO3).” NCT00486512 ↗ |
| Known as | Calcijex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00062699 ↗ |
| Known as | Compound 31543 | “Compound 31543 (topical calcitriol)” NCT01588522 ↗ |
| Known as | DN101 | “OBJECTIVE: To evaluate the preliminary efficacy, safety, and impact on quality of life (QoL) of high-dose calcitriol (DN-101) combined with mitoxantrone and glucocorticoids in...” PMID 18782306 ↗ Sep 20084“DN-101 is a unique formulation of calcitriol specifically designed for use in cancer.” NCT00066885 ↗ “calcitriol alone (DN101, 45 micrograms once weekly)” NCT00482157 ↗ “investigational study drug DN-101 (calcitriol)” NCT00536770 ↗ “DN-101 (calcitriol) - Drug” NCT00285675 ↗ |
| Known as | one alpha | “Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit” NCT01656512 ↗ |
| Known as | Rocaltrol | “We will enroll patients who have undergone cardiac transplantation into a randomized, double-blind, 12-month study of the efficacy and safety of calcitriol (Rocaltrol) and...” NCT00000412 ↗3“Daily dose of 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol, Rocaltrol; Roche, Basel, Switzerland), 75 mg acetylsalicylic acid (ASA), and 1250 mg calcium carbonate (CaCO3).” NCT00486512 ↗ “Daily vitamin D (cholecalciferol) tablets and rocaltrol” NCT00497900 ↗ |
| Known as | Vectical | “Vectical™ (Calcitriol) Ointment 3 µg/g and Clobex® (Clobetasol Propionate) Spray, 0.05%” NCT00988637 ↗ |
| Known as | Vitamin D | “Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit” NCT01656512 ↗ |
| Known as | vitamin D3 | “topical petrolatum (Vaseline) with calcitriol (vitamin D3) on a psoriatic lesion daily” NCT00004468 ↗ |
| Action | Inhibit | “vitamin D inhibition of renin transcription” NCT00585442 ↗ |
| Modality | Small molecule | “DN-101 is a pill containing calcitriol, a chemical related to vitamin D” NCT00055263 ↗ |
| Route | Oral | “Twice daily oral calcitriol with 1000 mg Calcium carbonate supplementation” NCT00001304 ↗ |
| Target | REN | “vitamin D inhibition of renin transcription” NCT00585442 ↗ |